Acid Sphingomyelinase Deficiency (ASMD) Market 规模与份额分析 - 成长趋势与预测 (2024 - 2031)
Acid Sphingomyelinase Deficiency (ASMD) Market is segmented By Therapy (XENPOZYME (olipudase alfa), Other Enzyme Replacement Therapies (ERT)), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned segments.
Acid Sphingomyelinase Deficiency (ASMD) Market Size
市场规模（美元） Mn
复合年增长率12.1%
| 研究期 | 2024 - 2031 |
| 基准年 | 2023 |
| 复合年增长率 | 12.1% |
| 市场集中度 | High |
| 主要玩家 | Sanofi, Orphazyme, Takeda Pharmaceutical, Actelion Pharmaceuticals and Among Others. |
*免责声明：主要玩家未按特定顺序列出。
*来源：Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Acid Sphingomyelinase Deficiency (ASMD) Market Analysis
The acid sphingomyelinase deficiency (ASMD) market is estimated to be valued at USD 134.6 Mn in 2024 and is expected to reach USD 300 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031. The market is expected to showcase significant growth during the forecast period due to the rising diagnosis of ASMD and growing access to enzyme replacement therapies.